<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1406222191
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOBUTAMINE JPI 250 mg/20 ml solution for IV infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOBUTAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        203.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01CA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dobutamine Concentrate belongs to a group of medicines known as inotropes, which make your heart beat more strongly.</p><p>&nbsp;</p><p><strong>In adults it is used:</strong></p><ul><li>In open heart surgery</li><li>To treat heart disease</li><li>To treat heart failure</li><li>In shock</li><li>As an alternative to exercise for stress testing the heart.</li></ul><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Dobutamine JPI is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given</strong><strong> Dobutamine JPI if you:</strong></p><ul><li>Are allergic to dobutamine, sodium metabisulfite or any of the other ingredients in this injection.</li><li>Suffer from high blood pressure due to a tumour near the kidney (Phaeocromocytoma).</li><li>Have certain heart or blood vessel disorders. dobutamine should not be used to detect poor blood supply to your heart (a cardiac stress test known as dobutamine stress echocardiography).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor or nurse if you have any of the following conditions:</p><ul><li>Have recently had a heart attack</li><li>Have had a heart transplant</li><li>Are asthmatic</li><li>Have unstable angina</li><li>Have heart disease</li><li>Have high blood pressure</li><li>Have any condition that would make exercise dangerous for you.</li></ul><p>&nbsp;</p><p><strong>Children </strong></p><p>Increments in heart rate and blood pressure appear to be more frequent and intense in children than in adults. The new-born baby cardiovascular system has been reported to be less sensitive to dobutamine and hypotensive effect (low blood pressure) seems to be more often observed in adult patients than in small children. Accordingly, the use of dobutamine in children should be monitored closely.</p><p>&nbsp;</p><p><strong>Other medicines and Dobutamine JPI</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. This is especially important with the following medicines as they may interact with your Dobutamine JPI:</p><ul><li>Beta blockers (medicines used to relieve certain heart conditions, anxiety and migraine).</li><li>Anaesthetics.</li><li>Entacapone (a medicine to treat Parkinson&rsquo;s Disease).</li></ul><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>You should not drive or use machinery if you are affected by the administration of Dobutamine JPI.</p><p>&nbsp;</p><p><strong>Dobutamine JPI contains </strong><strong>sodium metabisulfite and sodium</strong></p><p>Dobutamine JPI contains sodium metabisulfite.<strong> </strong>Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 4.8 mg sodium metabisulfite, which may rarely cause severe hypersensitivity reactions and bronchospasm.</p><p>&nbsp;</p><p>Dobutamine JPI contains sodium.<strong> </strong>Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 1.15 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per 20 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your nurse or doctor will give you the injection.</p><p>&nbsp;</p><p>Your doctor will decide the correct dosage for you and how and when the injection will be given.</p><p>&nbsp;</p><p>Since the injection will be given to you by a doctor or nurse, it is unlikely that you will be given too much. If you think you have been given too much, feel sick, are sick, feel anxious, feel palpitations, have a headache, feel short of breath or have chest pain you must tell the person giving you the injection.</p><p>&nbsp;</p><p><strong>Use in Children</strong></p><p>Your child will be given the injection by a nurse or doctor who will decide the correct dosage for your child and how and when the injection will be given.</p><p>&nbsp;</p><p>If you have any further questions or concerns on the use of this medicine for your child ask the doctor or nurse giving the injection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Your doctor will examine your heart before giving you dobutamine to decide if you are suitable to receive the drug.</p><p>&nbsp;</p><p><strong><em>The following side-effects have been reported:</em></strong></p><p><strong>Very common (more than 1 in 10 patients)</strong></p><ul><li>Increased heart rate</li><li>Chest pain</li><li>Heartbeat disturbances</li></ul><p>&nbsp;</p><p><strong>Common (in less than 1 in 10, but more than 1 in 100 patients)</strong></p><ul><li>Blood pressure increase or decrease</li><li>Narrowing of the blood vessels (vasoconstriction)</li><li>Irregular heartbeat (palpitations)</li><li>Asthma-like symptoms (bronchospasm)</li><li>Shortness of breath</li><li>Increase in white blood cells (eosinophilia)</li><li>Inhibition of blood clot formation</li><li>Rash (exanthema)</li><li>Fever</li><li>Inflammation of the vein at the injection site (phlebitis)</li></ul><p>&nbsp;</p><p><strong>Uncommon (in less than 1 in 100, but more than 1 in 1000 patients)</strong></p><ul><li>Fast contractions of the ventricles of the heart (ventricular tachycardia)</li><li>Uncontrolled contractions of the ventricles of the heart (ventricular fibrillation)</li><li>Heart attack (myocardial infarction)</li></ul><p>&nbsp;</p><p><strong>Very rare (in less than 1 in 10 000, including isolated cases)</strong></p><ul><li>Slow heartbeat (bradycardia)</li><li>Not enough blood supplied to the heart (myocardial ischaemia)</li><li>Low potassium (hypokalaemia)</li><li>Spots on the skin (petechial bleeding)</li><li>Heart block</li><li>Narrowing of the blood vessels supplying the heart (coronary vasospasm)</li></ul><p>&nbsp;</p><p><strong>Not known (cannot be estimated from the available data)</strong></p><ul><li>Chest pain caused by stress (stress cardiomyopathy)</li><li>Allergic reactions (hypersensitivity reactions) including symptoms of rash, fever, increase in white blood cells (eosinophilia) and asthma-like symptoms (bronchospasm)</li><li>Severe allergic reactions (anaphylactic reactions) and severe life-threatening asthmatic episodes possibly due to sensitivity to sodium metabisulfite (see section 2)</li><li>Muscle cramp (myoclonus) in patients with severe renal failure receiving dobutamine.</li><li>Abnormal heart function test (electrocardiogram ST segment elevation)</li><li>Inflammation of heart muscle (eosinophilic myocarditis) in heart transplant patients</li><li>Heart block (left ventricular outflow tract obstruction)</li><li>Fatal heart rupture</li><li>Restlessness</li><li>Feeling sick (nausea)</li><li>Headache</li><li>Pins and needles (paraesthesia)</li><li>Tremor</li><li>Increased desire to urinate (at high doses)</li><li>Feelings of heat and anxiety</li><li>Muscle cramp (myoclonic spasm)</li><li>Problems with your heart muscle (stress cardiomyopathy also known as Takotsubo syndrome) that present with chest pain, shortness of breath, dizziness, fainting, irregular heartbeat when dobutamine is used for stress echocardiography test.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>It is recommended that the solutions should be prepared right before use and administered right after its preparation. If any particular circumstances force the storage of the diluted solutions before use, it is recommended to be done within 24 hours of dilution at room temperature.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice that the solution is not clear and free of particles, or if the container is damaged.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is dobutamine hydrochloride.</p><p>&nbsp;</p><p>Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 280.24 mg dobutamine hydrochloride equivalent to 250 mg dobutamine.</p><p>&nbsp;</p><p>The other ingredients are sodium metabisulfite, hydrochloric acid solution, sodium hydroxide solution and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion is a clear colorless to pale straw-colored solution in 20 ml tubular type I clear glass vials with rubber stoppers and aluminum caps.  

Pack sizes: 1 Vial and/or 10 Vials (20 ml).

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2023; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي مركز الدوبيوتامين إلى مجموعة من الأدوية تعرف باسم مؤثرات التقلصات العضلية (الإنوتروبات)، والتي تجعل قلبك ينبض بقوة أكبر.</p><p>&nbsp;</p><p dir="RTL"><strong>يستخدم للبالغين:</strong></p><ul dir="rtl"><li>في جراحة القلب المفتوح</li><li>لعلاج أمراض القلب</li><li>لعلاج فشل القلب</li><li>في الصدمة</li><li>كبديل لممارسة التمارين عند إجراء اختبار الإجهاد للقلب.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>فئة الأطفال</strong></p><p dir="RTL">يُوصف دوبيوتامين الجزيرة لجميع فئات الأطفال العمرية (بدءاً من الأطفال حديثي الولادة وحتى من تبلغ أعمارهم 18 عامًا) باعتباره دعماً مُؤَثِّراً في التَّقَلصِ العَضَلِيّ في حالات نقص التروية الدموية للنتاج القلبي المنخفض الناتجة عن فشل القلب غير المعوض، الذي يتبع جراحة القلب، واعتلال عضلة القلب، وفي الصدمة القلبية أو الصدمة الإنتانية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطائك دوبيوتامين الجزيرة إذا:</strong></p><ul dir="rtl"><li>كنت تعاني من حساسية للدوبيوتامين، ميتابايسلفايت الصوديوم أو لأي من المواد الأخرى المستخدمة في تركيبة هذه الحقنة.</li><li>كنت تعاني من ارتفاع ضغط الدم نتيجة وجود ورم بالقرب من الكلى (ورم القواتم).</li><li>كنت تعاني من اضطرابات معينة في القلب أو في الأوعية الدموية. لا ينبغي استخدام دوبيوتامين للكشف عن ضعف ضخ الدم إلى قلبك (اختبار إجهاد القلب المعروف باسم تخطيط صدى القلب بالمجهود باستخدام دوبيوتامين).</li></ul><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات: </strong></p><p dir="RTL">تحدث مع طبيبك أو الممرض إذا كنت تعاني من أي من الحالات التالية:</p><ul dir="rtl"><li>أُصبت مؤخراً بنوبة قلبية</li><li>خضعت لإجراء زراعة قلب</li><li>إذا كنت مصاباً بالربو</li><li>لديك ذبحة صدرية غير مستقرة</li><li>تعاني من مرض في القلب</li><li>تعاني من ارتفاع في ضغط الدم</li><li>تعاني من أي حالة تعرضك للخطر عند ممارسة أي تمرين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">ارتفاعات في معدل ضربات القلب وضغط الدم تبدو أكثر تواتراً وشدة في الأطفال عن البالغين. تم الإبلاغ أن جهاز القلب والأوعية الدموية لدى الأطفال حديثي الولادة أقل حساسية للدوبيوتامين كما يبدو أن تأثير هبوط ضغط الدم (انخفاض ضغط الدم) كثيراً ما يلاحظ عند المرضى البالغين أكثر منه عند الأطفال الصغار. وبناءً على ذلك، يجب مراقبة تأثير استخدام دوبيوتامين على الأطفال عن كثب.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ودوبيوتامين الجزيرة</strong></p><p dir="RTL">أخبر طبيبك أو الممرض إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي يتم صرفها بدون وصفة طبية. يُعد ذلك أمرًا مهمًا خاصة مع الأدوية التالية، حيث يمكن أن تتفاعل مع دوبيوتامين الجزيرة:</p><ul dir="rtl"><li>حاصرات مستقبلات بيتا (أدوية تستخدم لتخفيف بعض حالات القلب، والقلق والصداع النصفي).</li><li>أدوية التخدير.</li><li>إنتاكابون (دواء يستخدم في علاج مرض باركنسون).</li></ul><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">اطلبي النصيحة من طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنت حاملاً أو مرضعاً، أو تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">يجب عليك الامتناع عن القيادة أو استخدام الآلات إذا تأثرت بإعطاء دوبيوتامين الجزيرة لك.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي دوبيوتامين الجزيرة على ميتابايسلفايت</strong> <strong>الصوديوم والصوديوم</strong></p><p dir="RTL">يحتوي دوبيوتامين الجزيرة على ميتابايسلفايت الصوديوم. يحتوي كل 20 مللتر من دوبيوتامين الجزيرة 250 ملغم/20 مللتر مركز للتخفيف للتسريب على 4.8 ملغم من ميتابايسلفايت الصوديوم، والذي نادراً ما قد يسبب ردود فعل تحسسية مفرطة وتشنج قصبي.</p><p>&nbsp;</p><p dir="RTL">يحتوي دوبيوتامين الجزيرة على الصوديوم. يحتوي كل 20 مللتر من دوبيوتامين الجزيرة 250 ملغم/ 20 مللتر مركز للتخفيف للتسريب على 1.15 ملغم من الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل 20 مللتر، وبذلك يمكن اعتباره&rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتولى الممرض أو الطبيب إعطاءك الحقنة.</p><p dir="RTL">سيقرر طبيبك الجرعة المناسبة لك وكيفية إعطاء الحقنة ووقت إعطائها.</p><p dir="RTL">من غير المرجح أن تحصل على جرعة زائدة، نظراً لأن الحقنة سيتم إعطاؤها لك من قبل الطبيب أو الممرض. إذا كنت تعتقد أنه تم إعطاؤك جرعة زائدة، أو كنت تشعر بالإعياء، أو التعب، أو تشعر بالقلق، أو تشعر بخفقان القلب، أو تعاني من الصداع، أو تشعر بضيق في التنفس أو تعاني من ألم في الصدر، فعليك أن تُخبر الشخص الذي يعطيك الحقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام لدى الأطفال</strong></p><p dir="RTL">سيقوم الممرض أو الطبيب بإعطاء الحقنة لطفلك والذي سيقرر بدوره الجرعة المناسبة لطفلك وكيفية إعطاء الحقنة ووقت إعطائها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أو مخاوف إضافية حول استخدام هذا الدواء لدى طفلك، يرجى استشارة الطبيب أو الممرض الذي يعطي الحقنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا إنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">سيفحص طبيبك قلبك قبل إعطائك دوبيوتامين ليقرر إذا ما كان يناسبك استخدام هذا الدواء أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong><em>تم الإبلاغ عن الآثار الجانبية التالية:</em></strong></p><p dir="RTL"><strong>شائعة جداً (أكثر من شخص من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>زيادة معدل نبضات القلب</li><li>ألم في الصدر</li><li>اضطرابات في نبضات القلب</li></ul><p>&nbsp;</p><p dir="RTL"><strong>شائعة (في أقل من شخص من كل 10 أشخاص، ولكن أكثر من شخص من كل 100 شخص)</strong></p><ul dir="rtl"><li>ارتفاع ضغط الدم أو انخفاضه</li><li>ضيق الأوعية الدموية (تضيق الأوعية)</li><li>عدم انتظام نبضات القلب (خفقان القلب)</li><li>أعراض تُشبه الربو (التشنج القصبي)</li><li>ضيق في التنفس</li><li>زيادة في خلايا الدم البيضاء (فرط الحمضات)</li><li>تثبيط تكوّن الجلطات الدموية</li><li>طفح (طفح ظاهر)</li><li>حمّى</li><li>التهاب الوريد عند موضع الحقن (التهاب وريدي)</li></ul><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة (في أقل من شخص من كل 100 شخص، ولكن أكثر من شخص من كل 1000 شخص)</strong></p><ul dir="rtl"><li>انقباضات سريعة في بطيني القلب (تسرع القلب البطيني)</li><li>انقباضات غير منضبطة في بطيني القلب (الرجفان البطيني)</li><li>نوبة قلبية (الاحتشاء القلبي)</li></ul><p>&nbsp;</p><p dir="RTL"><strong>نادرة جداً (في أقل من شخص من كل </strong><strong>&nbsp;10,000</strong><strong>شخص، بما في ذلك الحالات المنفردة)</strong></p><ul dir="rtl"><li>بطء نبضات القلب (خفقان القلب)</li><li>ضخ كمية غير كافية من الدم إلى القلب (إقفار عضلة القلب)</li><li>نقص البوتاسيوم (نقص بوتاسيوم الدم)</li><li>بقع على الجلد (نزف حبري)</li><li>إحصار القلب</li><li>ضيق الأوعية الدموية التي تضخ الدم إلى القلب (تشنج الشريان التاجي).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقديرها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>ألم في الصدر الذي يسببه الإجهاد (اعتلال عضلة القلب الإجهادي)</li><li>ردود فعل تحسسية (ردود فعل فرط الحساسية) تتضمن أعراض الطفح، والحمى، وزيادة خلايا الدم البيضاء (فرط الحمضات) وأعراض تُشبه الربو (التشنج القصبي)</li><li>ردود فعل تحسسية شديدة (ردود فعل تأقية) ونوبات ربو شديدة مهددة للحياة ربما بسبب الحساسية لميتابيسلفيت الصوديوم (انظر القسم 2)</li><li>تقلص عضلي (الرمع العضلي) في المرضى المصابين بالفشل الكلوي الشديد الذين يستخدمون دوبيوتامين</li><li>نتيجة غير طبيعية لاختبار وظائف القلب (ارتفاع مقطع ST على مخطط كهربية القلب)</li><li>التهاب عضلة القلب (التهاب عضلة القلب اليوزيني) لدى المرضى الذين خضعوا لجراحة زراعة القلب</li><li>إحصار القلب (انسداد مسالك تدفق البطين الأيسر)</li><li>تمزق القلب المميت</li><li>التململ</li><li>شعور بالإعياء (غثيان)</li><li>صداع</li><li>شعور بالوخز والتنميل (مذل)</li><li>ارتعاش</li><li>زيادة الرغبة في التبول (في الجرعات العالية)</li><li>شعور بالسخونة والقلق</li><li>تقلص عضلي (تشنج رمعي عضلي)</li><li>مشكلات بعضلة القلب (اعتلال عضلة القلب الإجهادي المعروف أيضاً باسم متلازمة تاكوتسوبو) التي تظهر مصحوبة بألم في الصدر، وضيق في التنفس، ودوخة، وإغماء، وعدم انتظام في ضربات القلب عند استخدام دوبيوتامين لإجراء اختبار تخطيط صدى القلب بالمجهود.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg;مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">يوصى بتحضير المحاليل قبل الاستخدام مباشرةً وإعطائها بعد تحضيرها مباشرةً. إذا فرضت أي ظروف معينة تخزين المحاليل المخففة قبل الاستخدام، يوصى أن يتم ذلك خلال 24 ساعة من التخفيف عند درجة حرارة الغرفة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن المحلول غير صافٍ أو خالٍ من الجزيئات، أو كانت العبوة تالفة.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد الدوبيوتامين.</p><p>&nbsp;</p><p dir="RTL">يحتوي كل 20 مللتر من دوبيوتامين الجزيرة 250 ملغم/ 20 مللتر مركز للتخفيف للتسريب<strong> </strong>على 280.24 ملغم هيدروكلوريد الدوبيوتامين يكافئ 250 ملغم دوبيوتامين.</p><p>&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي ميتابايسلفايت الصوديوم، محلول حمض الهيدروكلوريك، محلول هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">دوبيوتامين الجزيرة 250 ملغم/20 مللتر مركز للتخفيف للتسريب هو محلول صافٍ عديم اللون مائل إلى الأصفر الباهت في زجاجات أنبوبية شفافة من النوع رقم واحد بحجم 20 مللتر مع سدادات مطاطية وأغطية من الألومنيوم. &nbsp;</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">أحجام العبوات: زجاجة واحدة و/أو 10 زجاجات (20 مللتر).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p style="text-align:right">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة<br />إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم <img src="data:image/png;base64,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" alt="" width="126" height="26" vspace="0" hspace="0" border="0" style="width:126px;height:26px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />، فارفانسا<br />2705-906 تيروجيم</p><p dir="RTL">سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 2023/05؛ رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 280.24 mg dobutamine hydrochloride equivalent to 250 mg dobutamine. 

Excipients with known effect: Sodium metabisulfite and sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion is a clear colorless to pale straw-colored solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult population</u></p><p>Dobutamine JPI is indicated in adults who require inotropic support in the treatment of low output cardiac failure associated with myocardial infarction, open heart surgery, cardiomyopathies, septic shock and cardiogenic shock. Dobutamine JPI can also increase or maintain cardiac output during positive end expiratory pressure (PEEP) ventilation.</p><p>&nbsp;</p><p><u>Dobutamine stress echocardiography&nbsp;(Adult population only)</u></p><p>Dobutamine JPI may also be used for cardiac stress testing as an alternative to exercise in patients for whom routine exercise cannot be satisfactorily performed. This use of dobutamine should only be undertaken in units which already perform exercise stress testing and all normal care and precautions required for such testing are also required when using dobutamine for this purpose.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of Administration: For intravenous use only.</p><p>&nbsp;</p><p><u>Adult population</u></p><p>Dobutamine JPI must be diluted to at least 50 ml prior to administration in an IV container with one of the intravenous solutions listed below:</p><ul><li>5% Dextrose injection</li><li>10% Dextrose injection</li><li>5% Dextrose and 0.45% sodium chloride injection</li><li>5% Dextrose and 0.9% sodium chloride injection</li><li>Multi-electrolyte with 5% dextrose injection</li><li>Lactated Ringer&rsquo;s injection</li><li>5% Dextrose in lactated Ringer&#39;s injection</li><li>20% Mannitol in water for injection</li><li>0.9% sodium chloride injection</li><li>Sodium lactate injection</li></ul><p>&nbsp;</p><p>For example, diluting to 250 ml or 500 ml will provide the following concentrations for administration:</p><ul><li>250 ml contains 1,000 micrograms/ml of dobutamine</li><li>500 ml contains 500 micrograms/ml of dobutamine</li></ul><p>&nbsp;</p><p>The prepared solution should be used within 24 hours.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>Because of its short half-life, dobutamine is administered as a continuous intravenous infusion. After dilution, it should be administered through an intravenous needle or catheter using an IV drip chamber or other suitable metering device to control the rate of flow.</p><p>&nbsp;</p><p>Recommended dosage for adults and the elderly: The usual dose is 2.5 to 10 micrograms/kg/minute. Occasionally, a dose as low as 0.5 micrograms/kg/minute will produce a response.</p><p>&nbsp;</p><p>Rarely, up to 40 micrograms/kg/minute may be required.</p><p>&nbsp;</p><p>The rate of administration and the duration of therapy should be adjusted according to the patient&#39;s response as determined by heart rate, blood pressure, urine flow, and if possible, measurement of cardiac output.</p><p>&nbsp;</p><p>It is advisable to reduce the dosage of dobutamine hydrochloride gradually rather than abruptly stopping therapy.</p><p>&nbsp;</p><p>Side-effects, which are dose-related, are infrequent when dobutamine is administered at rates below 10 micrograms/kg/minute. Rates as high as 40 micrograms/kg/minute have been used occasionally without significant adverse effects.</p><p>&nbsp;</p><p>The final volume administered should be determined by the fluid requirements of the patient. Concentrations as high as 5,000 micrograms/ml have been used in patients on a restricted fluid intake. High concentrations of Dobutamine JPI should only be given with an infusion pump, to ensure accurate dosage.</p><p>&nbsp;</p><p><u>Cardiac stress testing&nbsp;(Adult population only)</u></p><p>When used as an alternative to exercise for cardiac stress testing the recommended dose is an incremental increase of 5 micrograms/kg/minute, from 5 up to 20 micrograms/kg/minute, each dose being infused for 8 minutes. Continuous ECG monitoring is essential and the infusion terminated in the event of &gt; 3 mm ST segment depression or any ventricular arrhythmia. The infusion should also be terminated if heart rate reaches the age/sex maximum, systolic blood pressure rises above 220 mm Hg or any side effects occur.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>For all paediatric age groups (neonates to 18 years) an initial dose of 5 micrograms/kg/minute, adjusted according to clinical response to 2 &ndash; 20 micrograms/kg/minute is recommended. Occasionally, a dose as low as 0.5-1.0 micrograms/kg/minute will produce a response.</p><p>&nbsp;</p><p>There is reason to believe that the minimum effective dosage for children is higher than for adults. Caution should be taken in applying high doses, because there is also reason to believe that the maximum tolerated dosage for children is lower than the one for adults. Most adverse reactions (tachycardia in particular) are observed when dosage was higher than/equal to 7.5 micrograms/kg/minute, but reducing or termination of the rate of dobutamine infusion is all that is required for rapid reversal of undesirable effects.</p><p>&nbsp;</p><p>A great variability has been noted between paediatric patients in regard to both the plasma concentration necessary to initiate a hemodynamic response (threshold) and the rate of hemodynamic response to increasing plasma concentrations, which demonstrates that the required dose for children cannot be determined a priori and should be titrated in order to allow for the supposedly smaller &ldquo;therapeutic width&rdquo; in children.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>For continuous intravenous infusion using an infusion pump, dilute to a concentration of 0.5 to 1 mg/ml (max 5 mg/ml if fluid restricted) with dextrose 5% or sodium chloride 0.9%. Infuse higher concentration solutions through central venous catheter only. Dobutamine intravenous infusion is incompatible with bicarbonate and other strong alkaline solutions.</p><p>&nbsp;</p><p><em>Neonatal intensive care:</em>&nbsp;Dilute 30 mg/kg body weight to a final volume of 50 ml of infusion fluid. An intravenous infusion rate of 0.5 ml/hour provides a dose of 5 micrograms/kg/minute.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to dobutamine, sodium metabisulfite or any of the other ingredients.
•	Phaeochromocytoma.
•	Dobutamine stress echocardiography
Dobutamine must not be used for detection of myocardial ischaemia and of viable myocardium in case of:
-	Recent myocardial infarction (within the last 30 days)
-	Unstable angina pectoris
-	Stenosis of the main left coronary artery
-	Haemodynamically significant outflow obstruction of the left ventricle including hypertrophic obstructive cardiomyopathy
-	Haemodynamically significant cardiac valvular defect
-	Severe heart failure (NYHA III or IV)
-	Predisposition for or documented medical history of clinically significant or chronic arrhythmia, particularly recurrent persistent ventricular tachycardia
-	Significant disturbance in conduction
-	Acute pericarditis, myocarditis or endocarditis
-	Aortic dissection
-	Aortic aneurysm
-	Poor sonographic imaging conditions
-	Inadequately treated / controlled arterial hypertension
-	Obstruction of ventricular filling (constrictive pericarditis, pericardial tamponade)
-	Hypovolaemia
-	Previous experience of hypersensitivity to dobutamine

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult population</u></p><p>If an undue increase in heart rate or systolic blood pressure occurs, or if an arrhythmia is precipitated, the dose of dobutamine should be reduced or the drug should be discontinued temporarily.</p><p>&nbsp;</p><p>Dobutamine may precipitate or exacerbate ventricular ectopic activity; rarely has it caused ventricular tachycardia or fibrillation. Because dobutamine facilitates A-V conduction, patients with atrial flutter or fibrillation may develop rapid ventricular responses.</p><p>&nbsp;</p><p>Particular care is required when administering dobutamine to patients with acute myocardial infarction, as any significant increase in heart rate or excessive increases in arterial pressure that occur may intensify ischaemia and cause anginal pain and ST segment elevation.</p><p>&nbsp;</p><p>Inotropic agents, including dobutamine, do not improve haemodynamics in most patients with mechanical obstruction that hinders either ventricular filling or outflow, or both. Inotropic response may be inadequate in patients with markedly reduced ventricular compliance. Such conditions are present in cardiac tamponade, valvular aortic stenosis, and idiopathic hypertrophic subaortic stenosis.</p><p>&nbsp;</p><p>Minimal vasoconstriction has occasionally been observed, most notably in patients recently treated with a &beta;-blocking drug. The inotropic effect of dobutamine stems from stimulation of cardiac &beta;<sub>1</sub>&nbsp;receptors and this effect is prevented by &beta;-blocking drugs. However, dobutamine has been shown to counteract the cardiodepressive effects of &beta;-blocking drugs. Conversely, adrenergic blockade may make the &beta;<sub>1</sub>&nbsp;and &beta;<sub>2</sub>&nbsp;effects apparent, resulting in tachycardia and vasodilatation.</p><p>&nbsp;</p><p><u>Dobutamine stress echocardiography</u></p><p>Because of possible life-threatening complications, the administration of dobutamine for stress echocardiography should only be undertaken by a physician with sufficient personal experience of the use of dobutamine for this indication.</p><p>&nbsp;</p><p>Stress cardiomyopathy (Takotsubo syndrome) is a possible severe complication of the use of dobutamine during stress echocardiography (see section 4.8). The administration of dobutamine for stress echocardiography should be only undertaken by a physician experienced with the procedure. The physician should be vigilant during the test and the recovery period and be prepared for appropriate therapeutic intervention during the test. In the event of stress cardiomyopathy (Takotsubo syndrome) dobutamine should be stopped immediately.</p><p>&nbsp;</p><p>The use of Dobutamine JPI as an alternative to exercise for cardiac stress testing is not recommended for patients with unstable angina, bundle branch block, valvular heart disease, aortic outflow obstruction or any cardiac condition that could make them unsuitable for exercise stress testing (see section 4.3)</p><p>&nbsp;</p><p>Cardiac rupture is a potential complication of myocardial infarction. The risk of cardiac rupture (septal and free wall) may be influenced by a variety of factors including site of, and time since, infarct. There have been very rare, fatal reports of acute cardiac rupture during dobutamine stress testing. These events have occurred during pre-discharge examination in patients hospitalised with recent (within 4-12 days) myocardial infarction. In the reported cases of free wall rupture, resting echocardiogram showed a dyskinetic and thinned inferior wall. Patients considered at risk of cardiac rupture during dobutamine testing should therefore be carefully evaluated prior to testing.</p><p>&nbsp;</p><p>Dobutamine stress echocardiography must be discontinued if one of the following diagnostic endpoints occurs:</p><ul><li>Reaching the age-predicted maximal heart rate [(220-age in years) x 0.85]</li><li>Systolic blood pressure decrease greater than 20 mmHg</li><li>Blood pressure increase above 220/120 mmHg</li><li>Progressive symptoms (angina pectoris, dyspnoea, dizziness, ataxia)</li><li>Progressive arrhythmia (e.g. coupling, ventricular salvos)</li><li>Progressive conduction disturbances</li><li>Recently developed wall motility disorders in more than 1 wall segment (16-segment model)</li><li>Increase of endsystolic volume</li><li>Development of repolarisation abnormality (due to ischaemia horizontal or down sloping ST segment depression more than 0.2 mV at an interval of 80 (60) ms after the J point compared to baseline, progressive or monophasic ST segment elevation above 0.1 mV in patients without a previous myocardial infarction</li><li>Reaching peak dose</li></ul><p>&nbsp;</p><p>In the event of serious complications (see section 4.8) dobutamine stress echocardiography must be stopped immediately.</p><p>&nbsp;</p><p>During the administration of Dobutamine JPI, as with any parenteral catecholamine, heart rate and rhythm, arterial blood pressure and infusion rate should be monitored closely. When initiating therapy, electrocardiographic monitoring is advisable until a stable response is achieved.</p><p>&nbsp;</p><p>Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to base-line values, but rarely intervention may be required and reversibility may not be immediate.</p><p>&nbsp;</p><p>Dobutamine JPI should be used with caution in the presence of severe hypotension complicating cardiogenic shock (mean arterial pressure less than 70 mm Hg).</p><p>&nbsp;</p><p>Hypovolaemia should be corrected when necessary with whole blood or plasma before administering dobutamine.</p><p>&nbsp;</p><p>If arterial blood pressure remains low or decreases progressively during administration of dobutamine despite adequate ventricular filling pressure and cardiac output, consideration may be given to the concomitant use of a peripheral vasoconstrictor agent, such as dopamine or noradrenaline.</p><p>&nbsp;</p><p><u>Dobutamine JPI contains</u><u> </u><u>sodium metabisulfite and sodium</u></p><p>Dobutamine JPI contains sodium metabisulfite.<strong> </strong>Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 4.8 mg sodium metabisulfite, which may rarely cause severe hypersensitivity reactions and bronchospasm.</p><p>&nbsp;</p><p>Dobutamine JPI contains sodium.<strong> </strong>Each 20 ml of Dobutamine JPI 250 mg/20 ml Concentrate for Solution for Infusion contains 1.15 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per 20 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Dobutamine has been administered to children with low-output hypoperfusion states resulting from decompensated heart failure, cardiac surgery, and cardiogenic and septic shock. Some of the haemodynamic effects of dobutamine hydrochloride may be quantitatively or qualitatively different in children as compared to adults. Increments in heart rate and blood pressure appear to be more frequent and intense in children. Pulmonary wedge pressure may not decrease in children, as it does in adults, or it may actually increase, especially in infants less than one year old. The neonate cardiovascular system has been reported to be less sensitive to dobutamine and hypotensive effect seems to be more often observed in adult patients than in small children.</p><p>&nbsp;</p><p>Accordingly, the use of dobutamine in children should be monitored closely, bearing in mind these pharmacodynamic characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Halogenated anaesthetics:</u></p><p>Although it is less likely than adrenaline to cause ventricular arrhythmias, Dobutamine JPI should be used with great caution during anaesthesia with cycloproprane, halothane and other halogenated anaesthetics.</p><p>&nbsp;</p><p><u>Entacapone:</u></p><p>The effects of Dobutamine JPI may be enhanced by entacapone.</p><p>&nbsp;</p><p><u>Beta-blockers:</u></p><p>The inotropic effect of dobutamine stems from stimulation of cardiac beta<sub>1</sub>&nbsp;receptors, this effect is reversed by concomitant administration of beta-blockers. Dobutamine has been shown to counteract the effect of beta-blocking drugs. In therapeutic doses, dobutamine has mild alpha<sub>1</sub>- and beta<sub>2</sub>-agonist properties. Concurrent administration of a non-selective beta-blocker such as propranolol can result in elevated blood pressure, due to alpha-mediated vasoconstriction, and reflex bradycardia. Beta-blockers that also have alpha-blocking effects, such as carvedilol, may cause hypotension during concomitant use of dobutamine due to vasodilation caused by beta<sub>2</sub>&nbsp;predominance (see section 4.4 Special warnings and precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reproduction studies in rats and rabbits have revealed no evidence of impaired fertility, harm to the foetus, or teratogenic effects due to dobutamine. As there are no adequate and well-controlled studies in pregnant women, and as animal reproduction studies are not always predictive of human response, dobutamine should not be used during pregnancy unless the potential benefits out weigh the potential risks to the foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable in view of the indications for use and the short half-life of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adult population</strong></p><p>Infusions for up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. There is evidence that partial tolerance develops with continuous infusions of dobutamine for 72 hours or more; therefore, higher doses may be required to maintain the same effects.</p><p>&nbsp;</p><p>Evaluation of undesirable effects is based on the following frequency scale:</p><table border="0" cellspacing="0" cellpadding="0" style="width:103%"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>&ge; 1/10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>&ge; 1/100 to &lt; 1/10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>&ge; 1/1,000 to &lt; 1/100</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>&ge; 1/10,000 to &lt; 1/1,000</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>&lt; 1/10,000</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>cannot be estimated from the available data</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Immune system disorders:</u></p></td></tr><tr><td style="vertical-align:top"><p>Not Known:</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity reactions including rash, fever, eosinophilia and bronchospasm have been reported. Anaphylactic reactions and severe life-threatening asthmatic episodes may be due to sulfite sensitivity (see section 4.4 Special warnings and other precautions for use).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Eosinophilia, inhibition of thrombocyte aggregation (only when continuing infusion over a number of days)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hypokalaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Paraesthesia, tremor, myoclonic spasm. Myoclonus has been reported in patients with severe renal failure receiving dobutamine</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Cardiac disorders / vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Increase of the heart rate by &ge; 30 beats/min</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Blood pressure increase of &ge; 50 mmHg. Patients suffering from arterial hypertension are more likely to have a higher blood pressure increase.</p><p>Blood pressure decrease, ventricular dysrhythmia, dose-dependent ventricular extrasystoles.</p><p>Increased ventricular frequency in patients with atrial fibrillation. These patients should be digitalised prior to dobutamine infusion.</p><p>Vasoconstriction in particular in patients who have previously been treated with beta receptor blockers.</p><p>Anginal pain, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular tachycardia, ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Bradycardia, myocardial ischaemia, myocardial infarction, cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Electrocardiogram ST segment elevation</p><p>Decrease in pulmonary capillary pressure</p><p>Eosinophilic myocarditis has been noted in explanted hearts of patients who had undergone treatment with multiple medications including dobutamine or other inotropic agents prior to transplantation.</p><p><u>Children:</u>&nbsp;pronounced increase of heart rate and/or blood pressure as well as a lower decrease of the pulmonary capillary pressure than adults. Increase of pulmonary capillary pressure in children under 1.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Restlessness, feeling of heat and anxiety</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Urinary urgency</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Dobutamine stress echocardiography</strong></p><p><u>Cardiac disorders / vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Pectoral anginal discomfort, ventricular extra-systoles with a frequency of &gt; 6/min</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Supraventricular extrasystoles, ventricular tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular fibrillation, myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Occurrence of a second degree atrioventricular block, coronary vasospasms.</p><p>Hypertensive/hypotensive blood pressure decompensation, occurrence of an intracavitary pressure gradient, palpitations</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Stress cardiomyopathy (Takotsubo syndrome) (see section 4.4)</p><p>Left ventricular outflow tract obstruction</p><p>Fatal cardiac rupture</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Respiratory system, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Bronchospasm, shortness of breath</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Exanthema</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Petechial bleeding</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Chest pain</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Increased urgency at high dosages of infusion</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Fever, phlebitis at the injection site</p><p>In case of accidental paravenous infiltration, local inflammation may develop.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Cutaneous necrosis</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>Paediatric population</strong></p><p>The undesirable effects include elevation of systolic blood pressure, systemic hypertension or hypotension, tachycardia, headache, and elevation of pulmonary wedge pressure leading to pulmonary congestion and edema, and symptomatic complaints.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdoses of dobutamine have been reported rarely. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath and anginal and non-specific chest pain. The positive inotropic and chronotropic effects of dobutamine may cause hypertension, tachyarrhythmias, myocardial ischaemia and ventricular fibrillation. Hypotension may result from vasodilatation.</p><p>&nbsp;</p><p>The duration of action of dobutamine is generally short (half-life, approximately 2 minutes). Dobutamine JPI should be temporarily discontinued until the patient&#39;s condition stabilises. The patient should be monitored and any appropriate resuscitative measures initiated promptly.</p><p>&nbsp;</p><p>Forced diuresis, peritoneal dialysis, haemodialysis, or charcoal haemoperfusion have not been established as beneficial.</p><p>&nbsp;</p><p>If the product is ingested, unpredictable absorption may occur from the mouth and gastrointestinal tract.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult population</u></p><p>Dobutamine directly stimulates &beta;-adrenergic receptors and is generally considered a selective &beta;<sub>1</sub>-adrenergic agonist, but the mechanisms of action of the drug are complex. It is believed that the &beta;-adrenergic effects result from stimulation of adenyl cyclase activity. In therapeutic doses, dobutamine also has mild &beta;<sub>2</sub>&nbsp;- and &alpha;<sub>1</sub>&nbsp;- adrenergic receptor agonist effects, which are relatively balanced and result in minimal net direct effect on systemic vasculature. Unlike dopamine, dobutamine does not cause release of endogenous norepinephrine. The main effect of therapeutic doses of dobutamine is cardiac stimulation. While the positive inotropic effect of the drug on the myocardium appears to be mediated principally via &beta;<sub>1</sub>-adrenergic stimulation, experimental evidence suggests that &alpha;<sub>1</sub>-adrenergic stimulation may also be involved and that the &alpha;<sub>1</sub>-adrenergic activity results mainly from the (-) -stereoisomer of the drug.</p><p>&nbsp;</p><p>The &beta;<sub>1</sub>-adrenergic effects of dobutamine exert a positive inotropic effect on the myocardium and result in an increase in cardiac output due to increased myocardial contractility and stroke volume in healthy individuals and in patients with congestive heart failure. Increased left ventricular filling pressure decreases in patients with congestive heart failure. In therapeutic doses, dobutamine causes a decrease in peripheral resistance; however, systolic blood pressure and pulse pressure may remain unchanged or be increased because of augmented cardiac output. With usual doses, heart rate is usually not substantially changed. Coronary blood flow and myocardial oxygen consumption are usually increased because of increased myocardial contractility.</p><p>&nbsp;</p><p>Electrophysiologic studies have shown that dobutamine facilitates atrio-ventricular conduction and shortens or causes no important change in intraventricular conduction. The tendency of dobutamine to induce cardiac arrhythmias may be slightly less than that of dopamine and is considerably less than that of isoproterenol or other catecholamines. Pulmonary vascular resistance may decrease if it is elevated initially and mean pulmonary artery pressure may decrease or remain unchanged. Unlike dopamine, dobutamine does not seem to affect dopaminergic receptors and causes no renal or mesenteric vasodilatation; however, urine flow may increase because of increased cardiac output.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Dobutamine also exhibits inotropic effects in children, but the haemodynamic response is somewhat different than that in adults. Although cardiac output increases in children, there is a tendency for systemic vascular resistance and ventricular filling pressure to decrease less and for the heart rate and arterial blood pressure to increase more in children than in adults. Pulmonary wedge pressure may increase during infusion of dobutamine in children 12 months of age or younger.</p><p>&nbsp;</p><p>Increases in cardiac output seems to begin at iv infusion rates as low as 1.0 micrograms/kg/minute, increases in systolic blood pressure at 2.5 micrograms/kg/minute, and heart rate changes at 5.5 micrograms/kg/minute.</p><p>&nbsp;</p><p>The increase of dobutamine infusion rates from 10 to 20 micrograms/kg/minute usually results in further increases in cardiac output.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adult population</u></p><p>Absorption: Orally administered dobutamine is rapidly metabolised in the GI tract. Following IV administration, the onset of action of dobutamine occurs within 2 minutes. Peak plasma concentrations of the drug and peak effects occur within 10 minutes after initiation of an IV infusion. The effects of the drug cease shortly after discontinuing an infusion.</p><p>&nbsp;</p><p>Distribution: It is not known if dobutamine crosses the placenta or is distributed into milk.</p><p>&nbsp;</p><p>Elimination: The plasma half-life of dobutamine is about 2 minutes. Dobutamine is metabolised in the liver and other tissues by catechol-o-methyltransferase to an inactive compound, 3-0-methydobutamine and by conjugation with glucuronic acid. Conjugates of dobutamine and 3-0-methyldobutamine are excreted mainly in urine and to a minor extent in faeces.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In most paediatric patients, there is a log-linear relationship between plasma dobutamine concentration and hemodynamic response that is consistent with a threshold model.</p><p>&nbsp;</p><p>Dobutamine clearance is consistent with first-order kinetics over the dosage range of 0.5 to 20 micrograms/kg/minute. Plasma dobutamine concentration can vary as much as two-fold between paediatric patients at the same infusion rate and there is a wide variability in both the plasma dobutamine concentration necessary to initiate a hemodynamic response and the rate of hemodynamic response to increasing plasma concentrations. Therefore, in clinical situations dobutamine infusion rates must be individually titrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No further information other than that which is included in the Summary of Products Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Sodium metabisulfite</p><p>-&nbsp;&nbsp; Hydrochloric acid solution</p><p>-&nbsp;&nbsp; Sodium hydroxide solution</p><p>-&nbsp;&nbsp; Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not add Dobutamine JPI to 5% sodium bicarbonate intravenous infusion BP or to any other strongly alkaline solutions. Because of potential physical incompatibilities, it is recommended that dobutamine hydrochloride not be mixed with other drugs in the same solution.</p><p>&nbsp;</p><p>Dobutamine JPI should not be used with other agents or diluents containing both sodium metabisulfite and ethanol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.

Following dilution in the recommended diluents (see section 4.2), chemical and physical in-use stability has been demonstrated for 24 hours at room temperature at 20-25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package.</p><p>&nbsp;</p><p>If any particular circumstances force the storage of the diluted solutions before use, it is recommended to be done within 24 hours of dilution at room temperature.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 ml tubular type I clear glass vials with rubber stoppers and aluminum caps.&nbsp;</p><p>&nbsp;</p><p>Pack sizes: 1 Vial and/or 10 Vials (20 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@JPI.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13 November 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>